Summary
Sixteen women with advanced epithelial ovarian carcinoma were treated with Aclacinomycin-A 40 mg/M2 given as a weekly infusion for four consecutive weeks followed by a two week rest period. All had failed prior chemotherapy. No responses were observed. Nausea and vomiting were the most frequent side effect. Myelo-suppression was minimal. This dose and schedule of Aclacinomycin-A are not recommended for further trials in ovarian carcinoma.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Hori S, Shirai M, Hirano S, Oki T, Inui T, Tsukagoshi S, Ishizuka M, Takeuchi T, Umezawa H: Antitumor activity of new anthracycline antibiotics, aclacinomycin-A and their toxicity. Gann 68(5):685–690, 1977
Levey BA, Ruiz E, Rogerson B, Lehotay DC, Levey GS: Failure of aclacinomycin and 7-con-o-methylnogarol (7-OMEN) to decrease cardiac guanylate cyclase activity. Cancer Treat Rep 64:1127–1128, 1980
Oki T, Matsuzawa Y, Yoshimoto A, Numata K, Kitamura I: New antitumor antibiotics aclacinomycins A and B. J Antibiot (Tokyo) 28(10):830–834, 1975
Kumai K, Kubota T, Ishibiki K, Abe O: Experimental and clinical studies on aclarubicin in the treatment of solid tumors. Biomed Pharmacother 38(7):332–337, 1984
Karanes C, Young JD, Samson MK, Smith LB, Franco LA, Baker LH: Phase I trial of aclacinomycin-A a clinical and pharmacokinetic study. Invest New Drugs: 1:173–179, 1983
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Martino, S., Decker, D.A., Hynes, H.E. et al. Phase II evaluation of Aclacinomycin-A in advanced ovarian carcinoma. Invest New Drugs 5, 373–374 (1987). https://doi.org/10.1007/BF00169977
Issue Date:
DOI: https://doi.org/10.1007/BF00169977